NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $68.27 +0.99 (+1.47%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$68.25 -0.02 (-0.03%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TransMedics Group Stock (NASDAQ:TMDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TransMedics Group alerts:Sign Up Key Stats Today's Range$66.23▼$69.6950-Day Range$60.82▼$79.4252-Week Range$55.00▼$177.37Volume630,932 shsAverage Volume1.32 million shsMarket Capitalization$2.30 billionP/E Ratio72.63Dividend YieldN/APrice Target$122.70Consensus RatingModerate Buy Company OverviewTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More… Remove Ads TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 52% of companies evaluated by MarketBeat, and ranked 589th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingTransMedics Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageTransMedics Group has only been the subject of 2 research reports in the past 90 days.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth43.00% Earnings GrowthEarnings for TransMedics Group are expected to grow by 43.00% in the coming year, from $1.00 to $1.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 72.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.54.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 72.63, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.40.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 16.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted30.60% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in TransMedics Group has recently increased by 2.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted30.60% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in TransMedics Group has recently increased by 2.36%, indicating that investor sentiment is decreasing. News and Social Media2.3 / 5News Sentiment0.13 News SentimentTransMedics Group has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 47 news articles for TransMedics Group this week, compared to 15 articles on an average week.Search InterestOnly 25 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows6 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesJim Cramer Finds TransMedics Group, Inc. (TMDX) Interesting but Expensive – Caution Advised!April 1 at 7:53 PM | finance.yahoo.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Lawsuit – TMDXApril 1 at 1:44 PM | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 2, 2025 | Porter & Company (Ad)TMDX COURT REMINDER: Lose Money on TransMedics Group? Investors are Reminded to Contact BFA Law before April 15 Class Action Deadline (NASDAQ:TMDX)April 1 at 8:33 AM | globenewswire.comTransMedics Group, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 15, 2025 to Discuss Your Rights - TMDXApril 1 at 5:45 AM | prnewswire.comTMDX COURT ALERT: TransMedics Group Investors are Notified to Contact BFA Law about the Pending Class Action LawsuitMarch 31 at 8:30 PM | markets.businessinsider.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – TMDXMarch 31 at 8:11 PM | globenewswire.comTransMedics Group (TMDX) Shares Down 60% From Class Period High, Class-Action Suit Pending – Hagens BermanMarch 31 at 7:04 PM | globenewswire.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $62.35 at the start of the year. Since then, TMDX stock has increased by 9.5% and is now trading at $68.27. View the best growth stocks for 2025 here. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings data on Monday, October, 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by $0.17. The company's quarterly revenue was up 63.7% compared to the same quarter last year. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings10/28/2024Today4/02/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$122.70 High Stock Price Target$178.00 Low Stock Price Target$75.00 Potential Upside/Downside+79.7%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$1.01 Trailing P/E Ratio72.63 Forward P/E Ratio68.27 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins8.14% Pretax Margin8.14% Return on Equity18.74% Return on Assets4.39% Debt Debt-to-Equity Ratio2.42 Current Ratio8.20 Quick Ratio7.33 Sales & Book Value Annual Sales$441.54 million Price / Sales5.20 Cash Flow$0.13 per share Price / Cash Flow530.08 Book Value$4.20 per share Price / Book16.25Miscellaneous Outstanding Shares33,662,000Free Float31,213,000Market Cap$2.30 billion OptionableOptionable Beta2.12 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:TMDX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.